Episode 306: Chemo/Nivo as a Bladder Sparing Approach in UC

Dr. Matt Galsky discusses his phase 2 study evaluating the effects of gemcitabine, cisplatin, and nivolumab followed by nivolumab in responders. Dr. Galsky explains how this treatment approach may potentially render cystectomy unnecessary in some cases.

Dr. Galsky is the Director of Genitourinary Medical Oncology and Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute.